446 related articles for article (PubMed ID: 28978939)
1. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
[TBL] [Abstract][Full Text] [Related]
2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.
Hioe CE; Kumar R; Upadhyay C; Jan M; Fox A; Itri V; Peachman KK; Rao M; Liu L; Lo NC; Tuen M; Jiang X; Kong XP; Zolla-Pazner S
Front Immunol; 2018; 9():2441. PubMed ID: 30416503
[TBL] [Abstract][Full Text] [Related]
4. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
5. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
[TBL] [Abstract][Full Text] [Related]
7. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
[TBL] [Abstract][Full Text] [Related]
8. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
[TBL] [Abstract][Full Text] [Related]
9. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
10. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
11. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
Doria-Rose NA; Bhiman JN; Roark RS; Schramm CA; Gorman J; Chuang GY; Pancera M; Cale EM; Ernandes MJ; Louder MK; Asokan M; Bailer RT; Druz A; Fraschilla IR; Garrett NJ; Jarosinski M; Lynch RM; McKee K; O'Dell S; Pegu A; Schmidt SD; Staupe RP; Sutton MS; Wang K; Wibmer CK; Haynes BF; Abdool-Karim S; Shapiro L; Kwong PD; Moore PL; Morris L; Mascola JR
J Virol; 2016 Jan; 90(1):76-91. PubMed ID: 26468542
[TBL] [Abstract][Full Text] [Related]
12. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.
Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
14. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.
Costa MR; Pollara J; Edwards RW; Seaman MS; Gorny MK; Montefiori DC; Liao HX; Ferrari G; Lu S; Wang S
J Virol; 2016 Nov; 90(22):10362-10378. PubMed ID: 27630232
[TBL] [Abstract][Full Text] [Related]
15. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
16. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
18. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
19. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]